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Purpose: Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a 
high recurrence rate and poor response to treatment. This study analyzes a consecutive 
series of ACC patients to evaluate the prognostic value of various clinical and patholog-
ical characteristics.
Methods: We retrospectively evaluated 32 ACC patients followed at our Medical Center 
from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, 
tumor functional status, stage, and type of treatment with respect to overall survival (OS) 
and disease-free survival (DFS), as determined by Kaplan–Meier curves.
results: ACC was associated with hormonal overproduction in 50% of cases, and 
patients with isolated hyperandrogenism had a better prognosis. Recurrence was 
observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size 
[hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12–1.64; p = 0.007], ki-67 (HR 
1.06, 95% CI 1.02–1.11; p = 0.009) and advanced stage at diagnosis (III–IV) (HR 6.51, 
95% CI 1.65–24.68; p = 0.006) were associated with recurrence in the 26 R0 patients 
in the univariate analysis. Advanced stage was an independent risk factor for recurrence 
in the multivariate analysis (HR 8.10, 95% CI 1.55–41.35; p = 0.01). Five-year survival 
was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02–38.31; p = < 0.001), 
ki-67 (HR 1.04, 95% CI 1.01–1.07; p = 0.01) and advanced stage (HR 11.31, 95% CI 
1.45–87.76; p = 0.02) were associated with poor survival in all 32 patients, but only 
positive resection margins were an independent predictor of mortality in the multivariate 
analysis (HR 6.22, 95% CI 1.44–26.05; p = 0.01).
conclusion: ACC has a poor prognosis with a high recurrence rate. Tumor stage at diag-
nosis and the completeness of surgical excision are the most relevant prognostic factors.
Keywords: adrenocortical carcinoma, adrenal cancer, prognostic factors, recurrence, survival
inTrODUcTiOn
Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of approximately 0.7–2 cases/
million inhabitants per year (1–3). The clinical presentation is characterized by functional symptoms 
related to adrenal hormone overproduction (Cushing’s syndrome, hyperandrogenism, and hyper-
aldosteronism) and/or by local symptoms due to compression by the tumor mass. Sometimes, the 
diagnosis can be an incidental finding after abdominal imaging.
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ACC is one of the most aggressive solid tumors, and complete 
surgical resection (which implies localized disease) is the cura-
tive treatment that offers the best hope for long-term survival. 
However, ACC remains a challenging malignancy because of the 
high frequency of recurrent disease and the low rate of response 
to postsurgical therapies (3–6). The estimated 5-year overall 
survival (OS) rate ranges from 16 to 44%, decreasing to less than 
13% in patients with metastatic disease (3–6).
In spite of promising advances in molecular characterization 
and therapeutic approaches, the ACC outcome remains poor. 
Therefore, reporting the clinical experience of even a limited 
number of cases might be useful in attempts to provide an accu-
rate prognosis and better care for this rare but aggressive disease.
In this retrospective study, we analyzed the clinical and patho-
logical features of a consecutive series of 32 patients affected by 
ACC followed at our Medical Center. These features were evalu-
ated with respect to their relevance to outcome and prognosis.
MaTerials anD MeThODs
Patient records and Follow-up
We retrospectively analyzed the clinical characteristics at pres-
entation, treatment, and outcome of a continuous series of 32 
ACC patients followed at our Medical Center from 1997 to 2015. 
Clinical records were reviewed and data on age at diagnosis, 
gender, functional tumor status (assessed by cortisol, aldosterone, 
and androgen levels), tumor size, stage at diagnosis as well as 
treatment details and outcome were analyzed. Some preoperative 
findings, as radiological reports, were not included in the analysis 
because they were performed by different centers and with non-
standardized procedures.
All patients underwent surgical resection of the ACC via the 
open or laparoscopic approach (on the basis of tumor size or 
preoperative imaging findings) at the Surgical Oncology Unit of 
our Medical Center.
Tumor specimens were reviewed by our pathologists and 
staged according to the ENSAT staging system (7), which defines 
stage I ACC as measuring ≤5  cm and confined to the adrenal 
gland, stage II as intra-adrenal ACC >5 cm, stage III by the pres-
ence of regional nodal involvement or local invasion (infiltration 
of surrounding tissue or vascular tumor extension), and stage IV 
by evidence of distant metastases. Resection margins status (the 
distance between the tumor and the edge of the surrounding tissue 
removed with the tumor) was evaluated by reviewing pathologi-
cal specimens and defined as follows: R0, no evidence of tumor; 
R1, microscopically positive resection margins; R2, macroscopic 
residual disease. Ki-67 was also measured in 19 patients.
All patients were followed up at our Medical Center. The 
postoperative evaluation included adrenal hormonal assessment 
(urinary free cortisol, androgens, and aldosterone were measured 
by commercially available competitive enzyme immunoassay or 
radioimmunoassay with intra- and inter-assay coefficients of 
variation for all assays <5 and <10%, respectively) and mor-
phological staging (CT or RMN, bone scan, and/or FDG PET 
scan); in the absence of biochemical and/or radiological signs 
of persistent/recurrent disease patients were considered free of 
disease. Adjuvant therapy with mitotane (o,p-DDD, Lysodren 
500  mg tablets, Laboratoire HRA Pharma, France) was started 
in 17 patients according to tumor stage and histopathological 
features of aggressiveness (tumor size >8 cm, ki-67 >10%). This 
treatment was not given to five patients free of disease but diag-
nosed before 2001, when mitotane was not available at our Center 
(3, 8). Adjuvant radiotherapy after surgery was not administered 
in our patients.
Patients were followed every 3–6 months by clinical, hormonal 
(in secreting tumors), and imaging evaluations. All patients with 
persistent/recurrent disease had undergone surgery or systemic 
therapy (mitotane and/or chemotherapy). Patients treated with 
mitotane underwent adrenal replacement therapy with cortisone 
acetate (cortone acetato 25 mg tablets, Teofarma, Italy) and fludro-
cortisone acetate (florinef 0.1 mg tablets, Bristol–Myers Squibb, 
Switzerland). Mitotane treatment was started at a low dosage (9) 
and then increased with the objective of achieving an adequate 
therapeutic range (14–20 mg/l) (10). Mitotane serum levels were 
routinely measured using the Lysosafe service provided by HPA 
Pharma.1 In 15 cases presented at the Medical Oncology Unit of 
our Medical Center, systemic chemotherapy [etoposide/doxoru-
bicin/cisplatin (EDP) regimen] was prescribed for progressive/
non-responsive disease. Progressive or stable disease was defined 
according to RECIST Criteria 1.1. OS time was calculated from 
the date of diagnosis to the date of death or to the last follow-up 
for censored patients. Disease-free survival (DFS) was measured 
in R0 patients from the date of diagnosis to the date of recurrence.
statistical analysis
Quantitative data are shown as mean ±  SD, and numbers and 
percentages are provided for qualitative data. Percentages were 
compared using chi-squared tests, and Student’s t-test was used 
for continuous variables. Univariate and multivariate analyses 
were performed using the Cox proportional hazards regression 
model. The results are reported with hazard ratio (HR) and 95% 
confidential intervals (CI). The OS and DFS curves were deter-
mined by the corresponding Kaplan–Meier curves. All tests were 
two-sided, and p values <0.05 were considered statistically sig-
nificant. Statistical analysis was performed using SPSS software, 
version 13.0 for Windows (SPSS Inc., Chicago, IL, USA).
resUlTs
clinical and hormonal status at 
Presentation
Table 1 summarizes the clinical and histopathological features of 
the 32 consecutive ACC patients (F = 22, M = 10, F/M ratio = 2.2) 
included in this retrospective study. The mean age at diagnosis was 
48.5 ± 16.5 years (median 51.4, range 19.9–78.9 years): younger 
in females (43.6 ± 15.5) than in males (59.8 ± 14.0; p = 0.01) and 
in patients with secreting tumors (n = 16) relative to patients with 
non-functioning tumors (n = 16) (40.2 ± 14.7 vs. 56.7 ± 14.2, 
respectively; p = 0.003).
1 www.lysosafe.com
TaBle 2 | comparison between the acc patients subdivided according 
to the type of endocrine function.a
Only androgens cortisol with or 
without androgens
non-functioning
N 7 8 16
Age at diagnosis 31.6 ± 7.3 45.7 ± 16.4* 56.7 ± 14.2***
Tumor size 8.9 ± 4.5 10.3 ± 4.8 9.9 ± 5.0
R1–2 0 2 3
Stage III–IV 2 4 7
Persistent/
recurrent 
disease
2 6 9
Progression/
death for 
disease
0 6** 9****
*p = 0.058 vs. androgens secreting tumors.
**p < 0.01 vs. androgens secreting tumors.
***p < 0.001 vs. androgens secreting tumors.
****p < 0.05 vs. androgens secreting tumors.
aOne patient secreting aldosterone is not included in this table.
TaBle 1 | clinicopathological characteristics in 32 acc patients.
Patients (%)
N 32
Male gender 10 (31.3)
Mean age at diagnosis (years) ± SD 48.5 ± 16.5
Mean tumor size (cm) ± SD 9.5 ± 4.7
Functioning tumors 16 (50.0)
Androgens and cortisol 6 (37.5)
Androgens alone 7 (43.7)
Cortisol alone 2 (12.5)
Aldosterone 1 (6.3)
ki-67 >10% 10 (52.6)a
R0 26 (81.3)
ENSAT stage
I 3 (9.3)
II 15 (46.9)
III 7 (21.9)
IV 7 (21.9)
aKi-67 analysis was performed in 19/32 cases.
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Among the patients with hormone-secreting tumors, most 
were females (15/22 or 68.2%), with only one case (1/10 or 
10.0%) of functioning AAC among the male patients (p = 0.006). 
In particular, androgen secretion was found in seven patients 
(43.7%). The secretion of cortisol alone was observed in only two 
patients (12.5%); the secretion of both androgens and cortisol was 
observed in six patients (37.5%); one case (6.3%) had hyperaldo-
steronism at diagnosis.
The clinical phenotype caused by the ACC was overt 
Cushing’s syndrome in five cases (15.2%) and hirsutism and 
oligoamenorrhea in eight cases (25%). Resistant hypertension 
with pronounced hypokalemia was found in the patient with 
the aldosterone-secreting carcinoma. Two patients with secret-
ing tumors were clinically asymptomatic. The non-functioning 
ACCs were revealed by abdominal discomfort and back pain in 
14 (43.7%) patients. Two non-functioning ACCs were diagnosed 
incidentally during abdominal imaging exams performed for 
other indications.
In the seven female patients with isolated hyperandrogenism, 
age at diagnosis was lower in patients with hypercortisolism 
(alone or in association with androgen issues) and those with 
non-functioning ACCs (Table 2). In this series, no patient had 
clinical or laboratory evidence of hereditary cancer syndromes 
associated with ACC (Li–Fraumeni syndrome, MEN-1, 
Beckwith–Wiedemann syndrome or familial adenomatous poly-
posis), although bilateral adrenal ACC was found in one patient.
surgical Treatment and  
histopathologic characteristics
Open surgery was performed on the primary tumor in 25 
patients (78.1%). In the remaining seven patients (21.9%) with 
a preoperative diagnosis suspicious of adenoma and an adrenal 
mass that was small in size (<4 cm), a laparoscopic approach was 
used for surgery. Negative resection margins (R0) were achieved 
in 26 patients (81.3%). Positive margins (R1) were found in 
two patients (6.3%). Macroscopically residual disease (R2) was 
present in the four remaining patients (12.5%).
Mean tumor size was 9.5  ±  4.7  cm (median 9.0, range 
3.5–25.0 cm) with no significant difference according to gender 
(cm 9.7 ± 5.2 in females vs. 9.4 ± 3.7 in males; p = 0.9) or ACC 
endocrine function (secreting vs. non-secreting tumors, 9.3 ± 4.6 
vs. 9.9 ± 5.0, respectively; p = 0.7).
Ki-67 values were quite variable, ranging from 2 to 80%; in 
10/19 cases (52.6%), the ki-67 value was >10%.
According to the ENSAT staging classification, only 3 patients 
were classified as stage I, 15 as stage II, 7 as stage III, and 7 as stage 
IV (Table 1). Distant metastases at diagnosis (M1) in stage IV 
patients were localized to liver (five patients), lung (six patients), 
bone (three patients), and peritoneum (one patient). Metastatic 
disease occurred during follow-up in 18 patients: liver and/or 
lung were affected in most cases (62.5%), followed by lymph 
nodes, bone, and peritoneum.
After surgery, 26 patients were R0: all patients with stage I, II, 
and III ACC and one patient with stage IV. Among the remaining 
six patients (18.8%, all with stage IV disease), tumor debulking 
but not complete removal of the primary tumor was achieved 
through surgery (Figure 1).
Postsurgical Therapy
After surgery, most (17/26 or 65.3%) R0 patients received adjuvant 
mitotane treatment (1 at stage I, 9 at stage II, 6 at stage III, and 1 
at stage IV) (Table 3). Mitotane serum levels in the therapeutic 
range (14–20  mg/l) were obtained in 10 cases (58.8%), while 
this target was not reached in the 7 remaining patients (41.2%) 
(5 patients did not tolerate the drug, and 2 patients had low 
compliance).
Chemotherapy was prescribed for the six R1–2 patients with 
persistent disease after surgery: a mitotane +  EDP regimen in 
four cases, mitotane alone or EDP alone in the remaining cases.
Outcome
Tumor Recurrence
Median DFS was 78.7  months (95% CI 10.1–147.3). Cancer 
recurrence was observed in 12 of the 26 R0 patients (46.2%) after 
TaBle 4 | cox proportional model for clinical-pathological parameters 
associated with recurrence in 26 r0 patients.
Univariate analysis Multivariate analysisa
Parameters hr (95% ci) p hr (95% ci) p
Male gender 2.51 (0.69–9.23) 0.2
Age at diagnosis 0.97 (0.92–1.12) 0.8
Functioning tumors 0.88 (0.19–2.56) 0.7
Mitotane therapy 1.42 (0.25–6.54) 0.7
Tumor size 1.32 (1.12–1.64) 0.007
Ki-67 1.06 (1.02–1.11) 0.009
Stage III–IV 6.51 (1.65–24.68) 0.006 8.10 (1.55–41.35) 0.01
aAdjusted for gender, age at diagnosis, functioning tumors, mitotane therapy, and 
stage. Ki-67 was not included in multivariate analysis since it was not available for all 
cases.
TaBle 3 | comparison between the 26 r0 patient in relationship to the 
adjuvant mitotane therapy.
adjuvant mitotane no adjuvant therapy p
N 17 9
Age at diagnosis 45.1 ± 16.0 53.9 ± 19.9 0.2
Tumor size 9.4 ± 3.8 8.4 ± 4.0 0.5
Functioning tumors 10 3 0.4
Stage III–IV 7 1 0.2
Recurrence 8 4 0.9
FigUre 1 | Treatment and outcome algorithm in our series of 32 acc patients. *The three disease-free patients at last control were treated with repeated 
surgery after recurrence.
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a median period of 19.4  months (range 3.0–108.6): 3 of these 
patients underwent a second surgical intervention because of 
localized disease, while 9 were treated with EDP in association 
with mitotane as first-line systemic chemotherapy.
ACC recurrence occurred in 8/17 R0 patients (47.1%) under 
adjuvant mitotane therapy and in 4/9 (44.4%) R0 patients not 
treated with mitotane (Table  3). The recurrence rate was not 
different among the 10 mitotane-treated patients that reached 
the therapeutic range (recurrence in 5/10) as compared to the 7 
patients that did not reach that target (recurrence in 3/7).
In the 26 R0 patients, the univariate analysis indicated that 
ACC recurrence was positively associated with tumor size (HR 
1.32, 95% CI 1.12–1.64; p =  0.007), ki-67 (HR 1.06, 95% CI 
1.02–1.11; p = 0.009), and advanced stage at diagnosis (III–IV 
vs. I–II: HR 6.51, 95% CI 1.65–24.68; p = 0.006) (Table 4). The 
multivariate analysis confirmed that advanced stage at diagnosis 
was an independent risk factor for recurrence (HR 8.10, 95% CI 
1.55–41.35; p = 0.01) (Table 4 and Figure 2).
Patient Survival
At the last control visit, after a median follow-up of 29.3 months 
(range 4.3–189.9), 17 patients (53.1%) were disease-free (3/3 
stage  I, 12/15 stage II, 1/7 stage III, and 1/7 stage IV), while 3 
patients (2/15 stage II and 1/7 stage III) showed progressive 
disease. Twelve patients died from the disease (1/15 stage II, 5/7 
stage III, and 6/7 stage IV). ACC patients with isolated hyperan-
drogenism had the lowest rate of progression/death for the disease 
compared with cortisol-secreting (p < 0.01) and non-functioning 
ACC patients (p < 0.05) (Table 2).
Overall survival at 3 and 5  years for the entire cohort was 
50.0 and 40.0%, respectively. At 5 years, OS was 85.7% for stage 
I–II patients, but only 16.7% for patients at stage III and 14% for 
patients at stage IV.
FigUre 2 | Kaplan–Meier survival curves for disease-free survival in 
the 26 r0 patients.
TaBle 5 | cox proportional model for clinicopathological parameters 
associated with mortality.
Univariate analysis Multivariate analysisa
Parameters hr (95% ci) p hr (95% ci) p
Male gender 3.12 (0.88–10.11) 0.06
Age at diagnosis 1.01 (0.90–1.15) 0.2
Functioning tumors 0.49 (0.22–1.63) 0.2
Mitotane therapy 0.65 (0.21–2.60) 0.6
Tumor size 1.14 (0.93–1.24) 0.1
≥8 cm 3.09 (0.77–11.49) 0.09
Ki-67 1.04 (1.01–1.07) 0.01
R1–2 10.61 (3.02–38.31) <0.001 6.22 (1.44–26.05) 0.01
Stage III–IV 11.31 (1.45–87.76) 0.02
aAdjusted for gender, age at diagnosis, functioning tumors, mitotane therapy, R status 
and stage. Ki-67 was not included in multivariate analysis since it was not available for 
all cases.
FigUre 3 | Kaplan–Meier survival curves for overall survival in all 32 
patients.
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The median OS for the entire cohort (n = 32) was 55.8 months 
(95% CI 9.0–97.3). For the six patients with persistent disease 
after surgery, median OS was only 7.7 months (95% CI 1.2–19.9) 
(Figure 1). Among the 12 R0 patients with recurrent disease, 3 
(all with repeated surgery) were disease-free at the last control 
visit; 3 had progressive disease, and 6 had died. All 14 R0 patients 
without tumor recurrence during follow-up were disease-free at 
the last control visit.
In the complete series of 32 patients, the univariate analysis 
indicated that poor survival was associated with positive margins 
of resection (HR 10.61, 95% CI 3.02–38.31; p < 0.001), ki-67 (HR 
1.04 95% CI 1.01–1.07; p = 0.01), and advanced stage (III–IV) at 
diagnosis (HR 11.31, 95% CI 1.45–87.76; p = 0.02). At multivari-
ate analysis, only resection margin positivity was an independent 
predictor of mortality (HR 6.22, 95% CI 1.44–26.05; p =  0.01) 
(Table 5; Figure 3).
DiscUssiOn
This study retrospectively analyzes a continuous series of ACC 
patients, all followed at a single Center from 1997 to 2015. The 
female/male ratio was 2.2:1, similar to that of other reports (4, 5). 
The mean age at diagnosis was significantly lower in females. This 
gender difference could be the consequence of the role of estro-
gens in adrenal tumorigenesis. Suggested mechanisms include 
the enhancement of adrenocortical cell proliferation mediated by 
17β-estradiol (11), the high expression of estrogen-related recep-
tor α (ERRα) in ACC tissues relative to normal adrenal cortex and 
to benign adrenal tumors (12), and the relevant role played by 
ERRα in 17β-estradiol and IGF-II-dependent ACC cell prolifera-
tion (13). These lines of evidence make ERRα a promising target 
for ACC therapy (14).
In our series, the ACC was functioning in 50.0% of patients, 
more frequently in women (68.2%), as already reported (15). In 
patients with functional ACC, the age at diagnosis was significantly 
lower, a likely consequence of the clinical signs and symptoms of 
hyperandrogenism, such as oligomenorrhoea or hirsutism, which 
made the diagnosis more evident in women. Since early diag-
nosis usually corresponds to stage I–II ACC, which has a better 
prognosis, many studies have found that functional status is an 
important prognostic factor. In our series, hormonal status was 
not a relevant prognostic factor, but subdividing patients accord-
ing to the type of hormonal secretion revealed that patients with 
isolated hyperandrogenism had better outcomes during follow-
up compared with patients with cortisol (alone or in combination 
with androgen)-secreting ACCs (Table  2). The less favorable 
prognosis of cortisol-secreting tumors is probably secondary to 
the immunosuppressive effect of the high cortisol levels (15, 16).
In contrast to previously published studies, in which most 
patients had ACC in advanced stages, in recent years, a shift 
toward more precocious stages, with the highest percentage of 
patients in stage II, has been observed. This is a likely consequence 
of the increased diffusion of radiological imaging procedures 
(17). However, despite earlier diagnosis, ACC is associated with a 
high percentage of recurrences even when surgical resection, the 
only curative approach, is apparently complete (17, 18).
The ACC recurrence rates reported in the literature are widely 
variable, ranging from 21 to 91% (19). This variability reflects 
the heterogeneity of the different series studied. Studies are often 
6Scollo et al. ACC Prognostic Factors
Frontiers in Endocrinology | www.frontiersin.org July 2016 | Volume 7 | Article 99
affected by selection bias and may include patients referred to 
specialized centers only after the development of recurrence (17). 
It is documented, in fact, that the management of ACC patients at 
highly specialized centers with more than 10 ACC cases treated 
each year is associated with improved survival and low recur-
rence rates (20).
ACC remains an aggressive cancer that can recur at any time, 
although most recurrences occur in the first 2 years after surgery 
(17). In our series, median recurrence time was 19.4  months, 
but the disease-free interval after surgery was quite variable 
(3.0–108.6 months). Tumor size, ki-67 index, and tumor stage 
are the risk factors significantly associated with recurrence 
(Table 4). In our series, adjuvant therapy with mitotane did not 
cause a significant benefit in terms of recurrence, but the small 
number of patients analyzed the possibility of selection bias, 
and unidentified interfering factors in the retrospective study 
do not allow strong conclusions. In a large series, Terzolo et al. 
have recently observed that adjuvant therapy with mitotane has 
an independent positive effect on recurrence-free survival (21). 
Therefore, in patients that are at high risk of recurrence (ki-67 
>10%, stage III–IV, tumor size >8 cm), mitotane is strongly rec-
ommended (3, 8, 22). The ki-67 proliferation index, assessed by 
immunohistochemistry, is a validated index of cell proliferation, 
and it is considered the most predictive histopathologic param-
eter of recurrence-free survival (3, 8, 22). Also our data (that 
showed a 6% additional risk of recurrence for each percentage 
point of ki-67 increase) confirm this relationship. A multicentric 
European study highlighted that a ki-67 threshold value at 10% 
represents a cut off to separate patients at low vs. high risk of 
recurrence (23).
In the high-risk patients, some evidences indicate that adju-
vant radiotherapy in the tumor bed after surgery significantly 
improved local control in resected ACC patients (24).
In low-risk patients, the indications for mitotane therapy are 
uncertain: current recommendations suggest assigning these 
patients to the randomized ADIUVO trial2 that compares mito-
tane treatment with a wait-and-see strategy (18, 22). Also, recur-
rence may occur among low-stage ACC patients: in our series, 
4/15 (26.7%) patients with stage II ACC experienced recurrence.
The optimal management of patients with recurrent ACC is 
not well established. A recent study showed that additional surgi-
cal procedures should be performed at first recurrence in patients 
with a DFS >12 months, when the tumor is completely resectable. 
In contrast, when recurrence occurs fewer than 6 months after 
disease diagnosis, the suggested treatment is aggressive medical 
therapy (25). In our series, three patients with cancer recurrence 
at 10.6, 19.4, and 31.4 months benefited from repeated surgery 
and were disease-free at the last control visit.
Despite an increased number of surgical procedures and earlier 
diagnosis, the survival rate of ACC patients has not significantly 
improved in recent years: the Netherlands Cancer Registry shows 
an average overall 5-year survival rate of 32% from 1993 to 2010; 
this figures jumps to 62% in patients with localized disease (6) 
and drops to 13% in patients with distant metastases (4, 15). The 
2 https://clinicaltrials.gov/ct2/show/NCT00777244
lack of improvement of OS during recent years is mainly due to 
the absence of new and effective therapies (26). In our series, 
the survival rate at 5 years was 40.0%. The individual prognosis 
largely depended on tumor stage, with OS decreasing markedly 
from 85.7% for stage I–II to 16.7 and 14% for patients at stages 
III and IV, respectively. These percentages are similar to those 
reported in larger series (2–6). However, multivariate analysis 
showed that incomplete tumor resection was the only independ-
ent parameter associated with mortality, highlighting that, at 
present, radical surgery is the only potentially curative therapy 
for this disease (27).
Our report and clinical experience remark that ACC patient 
prognosis is poor and largely depends by tumor stage at diagnosis, 
with strong relation with postoperative stadiation (e.g. margins 
status). The rate of recurrence is high. No effective medical 
therapies are available at present, and the current treatment with 
mitotane and conventional chemotherapy provides small benefits 
in most cases.
Recently, genomic studies led to the identification of genetic 
and epigenetic alterations characterizing subgroups of tumors 
with activation of specific molecular pathway patterns and with 
different clinical outcome. Based on these analyses, the prognostic 
stratification is more accurate than that obtained with the use of 
traditional prognostic factors. The use of genome-wide expression 
profile studies, microRNA, and methylation profile may allow a 
better prognostic prediction and promote the development of 
molecular-targeted therapies (28, 29).
Our study presents some limitations, the most important 
being the small series of patients, the retrospective design, and the 
analysis of prognostic factors restricted to traditional histological 
markers with no insight on the molecular profile of ACC.
cOnclUsiOn
• ACC is a rare disease, more frequent in women who have a 
younger mean age at diagnosis and a higher rate of function-
ing tumors.
• Functioning ACC are diagnosed earlier, but only ACC patients 
with isolated hyperandrogenism have a better prognosis, not 
patients with ACC secreting cortisol (alone or in combination 
with androgens).
• The completeness of surgery, without margin positivity, is a 
critical requirement to improve outcome. However, the recur-
rence rate is high, even when surgical resection is apparently 
complete. Tumor size, ki-67, and a high tumor stage are the 
risk factors significantly associated with ACC recurrence.
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